Bristol-Myers Squibb Company (BMY) · page 5 of 16
The slide argues against the Bristol-Myers/Celgene merger by highlighting the risk of patent cliffs.
Shareholder letter · expose_contradiction · expose_contradiction · dense density
Slide locked Sign in to view
Slide schematic 6/6
chart 2/2 paragraph 1/1 source-note 1/1 title 2/2
Components 6
line line paragraph source-note headline headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1